ScreenerHero

FBIO Fortress Biotech, Inc.

NAS · US · Healthcare · Biotechnology · fortressbiotech.com
2.040USD-0.49%Mkt Cap: 68.04M $P/E: 0.74

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule fo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap68.04M USD
Enterprise Value-32.94M USD
Revenue (TTM)68.47M USD
Gross Profit42.34M USD
Net Income (TTM)6.82M USD
Revenue/Share2.25 USD
Last Price2.040 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees78
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.74
P/E (Forward)-1.16
PEG—
EV/EBITDA1.32
EV/Revenue-0.48
P/S1.00
P/B0.42
EPS (TTM)2.76
EPS (Forward)-1.76
52W Range
2.0002% of range4.530
52W High4.530 USD
52W Low2.000 USD
Profitability
Gross Margin66.92%
Oper. Margin-53.46%
EBITDA Margin-36.48%
Profit Margin10.77%
ROE13.66%
ROA3.67%
Growth
Revenue Growth14.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-65.78M USD
CapEx (TTM)—
FCF Margin-25.03%
FCF Yield-25.19%
Net Debt-143.26M USD
Net Debt/EBITDA5.74
Balance Sheet
Debt/Equity1.49
Current Ratio3.96
Quick Ratio3.76
Book Value/Sh4.93 USD
Cash/Share5.89 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateOct 10, 2023
Analyst Consensus
Rating—
Target (Mean)5.000 USD
Upside (mean)+145.1%
Target Range5.000 USD – 5.000 USD
# Analysts1
Ownership
Shares Out.33.35M
Float21.44M
Insiders23.90%
Institutions31.43%
Short Interest
Short Ratio13.8d
Short % Float19.81%
Short % Out.15.31%
Shares Short5.11M
Short (prev mo.)5.58M
Technical
SMA 502.645 (-22.9%)
SMA 2002.957 (-31.0%)
Beta1.25
S&P 52W Chg16.45%
Avg Vol (30d)322.71K
Avg Vol (10d)291.85K
Technical Indicators
RSI (14)27.1
MACD-0.1937
MACD Signal-0.1805
MACD Hist.-0.0132
BB Upper2.759 USD
BB Middle2.324 USD
BB Lower1.889 USD
BB Width37.44%
ATR (14)0.1071 USD
Vol Ratio (20d)0.52x